Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor ...

Interested in the spatial research landscape, technological breakthroughs and future directions? Check out this interview ...

We studied the value of histopathologic tumor traits, in addition to stromal-compartment tumor infiltrating lymphocyte (sTIL) levels, in the risk stratification of young patients with node-negative ...

Bioengineer Ankur Singh works to create functional models of the human immune system in the lab. (Credit: Ankur Singh) ...

Researchers have deployed a method for mitochondrial transfer to overcome T-cell exhaustion during treatment of solid tumors.

Investigators have developed a way to 'supercharge' T cells by supplying them with extra mitochondria from multipotent stromal cells.

T cells refueled with extra mitochondria exhibited heightened antitumor activity and reduced signs of exhaustion in ...

本次ESMO大会进一步更新报道了中国桥接研究的数据。这项Ⅱ期研究招募了对伊马替尼治疗失败或不耐受的GIST成年患者，随机（1:1）接受瑞派替尼150 mg每日一次（QD）或舒尼替尼50 mg ...

ROCKVILLE, Md. and SUZHOU, China, Sept. 13, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical ...

Fighting cancer is exhausting for T cells. Hostile tumor microenvironments can drain their mitochondrial activity, leading to a condition known as T cell exhaustion. This phenomenon also hinders ...

亚盛医药 (6855.HK)今日宣布，公司已在2024年欧洲肿瘤内科学会 (ESMO)年会上，以小型口头报告 (mini oral)形式公布公司原创1类新药奥雷巴替尼 (商品名：耐立克®；研发代号：HQP1351)治疗琥珀酸脱氢酶 (succinate dehydrogenase, SDH)缺陷型胃肠间质瘤 (gastrointestinal stromal tumor, GIST)的临床研究成果 ...